Seffiline S.r.l.
(BO)
SEFFILINE was founded in 2018 with the aim of making autologous regenerative therapy accessible to everyone.
For some years, autologous regenerative therapy using mesenchymal stem cells of adipose origin has been considered a state-of-art technology, and is supported by an enormous scientific literature.
In 2019 SEFFILINE started producing and selling the first and only medical device that enables autologous regenerative therapy using mesenchymal stem cells of adipose origin.